Milwaukee Business Journal Highlights Foley’s Work in Foxconn Project
December 18, 2017
Milwaukee Business Journal
The Milwaukee Business Journal highlighted Foley’s work on behalf of the Wisconsin Economic Development Corporation in connection with Foxconn’s planned megacampus in Racine County, Wisconsin in the article, “WEDC Reveals Payment to Outside Counsel Foley & Larder for Foxconn Project.”
A WEDC spokesperson told the Business Journal that the Foxconn investment in Wisconsin is by far the largest economic development project in the state’s history, involving several international entities. “As a result, WEDC engaged with Foley & Lardner to ensure the contract clearly outlined the terms of the agreement negotiated between the parties with a specific emphasis on ensuring the state’s ability to enforce and collect on any potential clawbacks.”
A WEDC spokesperson told the Business Journal that the Foxconn investment in Wisconsin is by far the largest economic development project in the state’s history, involving several international entities. “As a result, WEDC engaged with Foley & Lardner to ensure the contract clearly outlined the terms of the agreement negotiated between the parties with a specific emphasis on ensuring the state’s ability to enforce and collect on any potential clawbacks.”
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.